Healthcare Capital Partners... Net Worth

The estimated Net Worth of Healthcare Capital Partners... is at least $51.7 millió dollars as of 6 February 2024. Healthcare Partners owns over 86,048 units of KalVista Pharmaceuticals Inc stock worth over $51,721,116 and over the last few years Healthcare sold KALV stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Healthcare Partners KALV stock SEC Form 4 insiders trading

Healthcare has made over 4 trades of the KalVista Pharmaceuticals Inc stock since 2024, according to the Form 4 filled with the SEC. Most recently Healthcare bought 86,048 units of KALV stock worth $1,258,022 on 6 February 2024.

The largest trade Healthcare's ever made was buying 99,129 units of KalVista Pharmaceuticals Inc stock on 22 January 2024 worth over $1,242,086. On average, Healthcare trades about 73,016 units every 3 days since 2024. As of 6 February 2024 Healthcare still owns at least 4,824,731 units of KalVista Pharmaceuticals Inc stock.

You can see the complete history of Healthcare Partners stock trades at the bottom of the page.

Insiders trading at KalVista Pharmaceuticals Inc

Over the last 8 years, insiders at KalVista Pharmaceuticals Inc have traded over $74,823,944 worth of KalVista Pharmaceuticals Inc stock and bought 4,877,063 units worth $58,591,487 . The most active insiders traders include Holdings A/S Novo, Capital Management, L.P.Ra ... és Rajeev M. Shah. On average, KalVista Pharmaceuticals Inc executives and independent directors trade stock every 19 days with the average trade being worth of $835,088. The most recent stock trade was executed by Benjamin L Palleiko on 6 September 2024, trading 15,625 units of KALV stock currently worth $167,500.

What does KalVista Pharmaceuticals Inc do?

kalvista is a clinical stage pharmaceuticals company focused on the discovery, development, and commercialization of small molecule protease inhibitors.

Complete history of Healthcare Partners stock trades at KalVista Pharmaceuticals Inc

KalVista Pharmaceuticals Inc executives and stock owners

KalVista Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Thomas Crockett,
  Chief Executive Officer, Director
• Edward Feener,
  Chief Scientific Officer
• Benjamin Palleiko,
  Chief Financial Officer, Chief Business Officer
• Thomas Andrew Crockett M.B.A.,
  CEO & Director
• Christopher Yea,
  Chief Development Officer
• Benjamin L. Palleiko,
  Chief Bus. Officer & CFO
• Dr. Christopher M. Yea Ph.D.,
  Chief Devel. Officer
• Martin Edwards,
  Independent Chairman of the Board
• Edward Unkart,
  Independent Director
• Arnold Oronsky,
  Independent Director
• Albert Cha,
  Independent Director
• Brian Pereira,
  Independent Director
• Daniel Soland,
  Independent Director
• Michael Smith,
  Senior Vice President - Development
• Andreas Maetzel,
  Senior Vice President - Medical
• Jarrod Aldom,
  VP of Corp. Communications
• John B. McKune,
  VP of Fin.
• Stephen Donnelly,
  Director of Fin. and Company Sec.
• Dr. Paul K. Audhya M.B.A., M.D.,
  Chief Medical Officer
• Dr. Michael D. Smith Pharm.D.,
  Sr. VP of Devel.
• Rachel Morten,
  Head of Regulatory Affairs and QA
• Leah Monteiro,
  Sr. Director of Corp. Communications & Investor Relations
• Dr. Edward P. Feener Ph.D.,
  Chief Scientific Officer
• Joshua Resnick,
  Director
• Iv, Llcsv Life Sciences Fun...,
  
• Capital Management, Llc Kol...,
  
• Capital Management, L.P.Ra ...,
  
• Rajeev M. Shah,
  Director
• Healthcare Capital Partners...,
  
• Holdings A/S Novo,
  10% owner
• William Fairey,
  
• Paul K. Audhya,
  CHIEF MEDICAL OFFICER
• Healthcare Capital Partners...,
  
• Nancy Stuart,
  Director
• Patrick Treanor,
  Director
• Brian Piekos,
  Chief Financial Officer
• Healthcare Capital Partners...,